ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC "
Episode Synopsis
CME credits: 0.50
Valid until: 11-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/
This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available. *Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.
Valid until: 11-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/
This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available. *Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.
In God we trust